Vela Genomics Launches NGS Clinical Interpretation and Reporting

SINGAPORE – 7 MARCH, 2017 – Vela Genomics, a subsidiary of Vela Diagnostics, has launched TheraKey™ which aims to provide accurate Next-Generation Sequencing (NGS) clinical interpretation and reporting.

Read more

Vela Genomics Launches Early Access to TheraKey™

SINGAPORE – 20 SEPTEMBER, 2016 – Vela Genomics, a subsidiary of Vela Diagnostics, announced today the availability of TheraKey™, a clinical interpretation reporting service, for early access customers.

Read more

Get The Latest Updates on Vela Genomics